Adaptin Bio Opens Enrollment in Phase 1 Trial of APTN-101 for EGFRvIII-Positive Glioblastoma
核心洞察
Adaptin Bio has opened enrollment in a first-in-human Phase 1 trial of APTN-101, a BRiTE (Brain Bispecific T cell Engager) therapy for glioblastoma (搜索), conducted in collaboration with Duke University (搜索).
The open-label, dose-escalation study will enroll up to 15 adults with WHO Grade IV malignant glioma expressing EGFRvIII (搜索), with safety and maximum tolerated dose as primary objectives.
APTN-101 is engineered to cross the blood-brain barrier and selectively target EGFRvIII (搜索), achieving complete tumor eradication in 70%-80% of mice in preclinical models.
Adaptin Bio, Inc. (搜索) (OTCQB: APTN) announced on August 20, 2026, that enrollment has opened for a Phase 1 clinical trial evaluating its proprietary BRiTE (Brain Bispecific T cell Engager) therapeutic, APTN-101, as a treatment for glioblastoma (搜索) (GBM), the most common and aggressive primary brain tumor. The BRiTE platform was developed by a team of researchers at Duke University (搜索), which serves as the study site for this first-in-human clinical trial.
APTN-101's unique mechanism of action is designed to overcome the limitations of effective treatment for malignant brain tumors by enhancing the transport of therapies across the blood-brain barrier and selectively targeting EGFRvIII (搜索)+ glioma cells.
Trial Design and Endpoints
The Phase 1 clinical trial uses an open-label, dose-escalation design with the primary objective of evaluating the safety profile and maximum tolerated dose of APTN-101 in patients diagnosed with World Health Organization (WHO) Grade IV Malignant Glioma (GBM that expresses Epidermal Growth Factor Receptor variant III [EGFRvIII (搜索)]). The study is expected to enroll up to 15 adult patients.
The primary endpoint is the proportion of patients with a dose-limiting toxicity observed within each dose level. Secondary endpoints include the pharmacokinetics of APTN-101 and the objective response rate based on modified Response Assessment in Neuro-Oncology Criteria. Exploratory endpoints include an assessment of biological activity as evidenced by changes in cytokine levels, formation of anti-BRiTE antibodies, overall survival, and progression-free survival.
Mechanism of Action and Preclinical Evidence
BRiTE's delivery mechanism and mode of action harness the ability of T cells to precisely target and destroy glioma cells while effectively navigating the brain's unique environment. Specifically, APTN-101 is engineered to cross the blood-brain barrier (BBB) to target EGFRvIII (搜索), a specific protein linked to aggressive brain tumors.
In preclinical studies, APTN-101 demonstrated a greater than 7-fold increase in distribution of the EGFRvIII (搜索) T-cell engager into the brain compared to the EGFRvIII T-cell engager alone. This resulted in complete eradication of EGFRvIII GBM tumors in 70%-80% of mice. The novel treatment is associated with an excellent safety profile and minimal off-target effects in preclinical models.
"Opening enrollment in the Phase 1 trial is an important milestone in the clinical development of APTN-101, a potential best-in-class therapy for the treatment of glioblastoma (搜索)," said Michael J. Roberts, Ph.D., President and CEO of Adaptin Bio. "In preclinical studies, APTN-101 demonstrated impressive efficacy targeting glioma cells with precision, eliminating some malignant glioma tumors across multiple aggressive disease models."
Unmet Need in Glioblastoma
Standard-of-care therapies, including surgery, radiotherapy, and chemotherapy, are not curative, and disease recurrence is common. As a result, patients diagnosed with GBM currently have a median survival of only 12 to 18 months, with just 5% of patients surviving beyond five years.
"Glioblastoma (搜索) is a disease with a significant unmet clinical need, limited therapeutic options, and little improvement in outcomes," said Mustafa Khasraw, M.D., professor at Duke University (搜索) School of Medicine, who led the preclinical development team for APTN-101 and serves as principal investigator of the upcoming clinical trial. "By combining immune-based tumor targeting with enhanced delivery to the brain, APTN-101 is designed to address two major challenges in glioblastoma treatment. This first-in-human study is an important step in determining whether this approach can translate into meaningful benefit for patients."
Glioblastoma (搜索) is one of the most aggressive and deadly forms of brain cancer, accounting for approximately 15,000 new cases per year in the U.S. Secondary malignant brain tumors account for about 200,000 new cases annually. The glioblastoma multiforme treatment market is valued at $3.02 billion in 2025, with researchers forecasting an 8% CAGR over the next five years, reaching $4.44 billion by 2030. Growing demand for therapies that prolong survival is a top driver of the projected growth.
About the BRiTE Platform
Adaptin Bio's proprietary BRiTE technology leverages the enhanced "hitchhiking" capabilities of manipulated immune cells to deliver therapeutic agents directly to brain tumors. This approach has demonstrated high specificity for EGFRvIII (搜索)-expressing glioma cells, dose-responsive efficacy against diverse patient-derived glioma cell lines, and a favorable safety profile. Additional BRiTE targets are being evaluated. By manipulating the immune system either in vivo or ex vivo, BRiTE aims to overcome traditional treatment barriers and offer a promising new therapeutic option for patients with intracerebral malignancies.